New Article by WTD Chairman Published in ‘The Lancet Haematology’
Extended Duration of Anticoagulation with Edoxaban in Patients with Venous Thromboembolism: A Post-Hoc Analysis of the Hokusai-VTE Study
By Gary Raskob, Walter Ageno, Alexander T Cohen, Marjolein P A Brekelmans, Michael A Grosso, Annelise Segers, Guy Meyer, Peter Verhamme, Philip S Wells, Min Lin, Shannon M Winters, Jeffrey I Weitz, Harry R Bueller
Background
There are few data on the relative efficacy and safety of direct oral anticoagulants, such as edoxaban, compared with vitamin K antagonists during extended therapy for venous thromboembolism. This analysis evaluates the risk–benefit of extended treatment for up to 12 months with edoxaban compared with warfarin among patients enrolled in the Hokusai-VTE study who continued therapy beyond 3 months.
*Article originally published in The Lancet Haematology
Share this post, choose a platform
Related Campaign News
Ann Marie O'Neill is the CEO and Founder of Thrombosis Ireland, [...]
A newly published paper in the journal Arteriosclerosis, Thrombosis, and Vascular [...]
In this series, World Thrombosis Day (WTD) shares interviews with members [...]
